Pharma BD Deal Intelligence
Roche acquired Poseida Therapeutics for $1.0B for cell therapy for cancer.
Poseida Therapeutics announces agreement to be acquired by Roche Holdings: $9.00/share cash plus CVR up to $4.00/share.
Major pharmaceutical company Roche buys cell and gene developer Poseida Therapeutics in $1.5 billion acquisition deal
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Roche (via subsidiary Blue Giant Acquisition Corp.) acquired San Diego-based cell-therapy developer Poseida Therapeutics in a tender-offer takeover announced 26 November 2024 and completed 8 January 2025. Holders received US$9.00 per share in cash at closing -- a total upfront equity value of approximately US$1.0 billion, a ~215% premium to Poseida's 25 November 2024 close -- plus a non-tradeable contingent value right (CVR) for up to an additional US$4.00 per share, bringing total potential deal value to approximately US$1.5 billion. The acquisition gives Roche Poseida's allogeneic (off-the-shelf) CAR-T platform and lead candidates P-BCMA-ALLO1 (BCMA-targeted, RMAT-designated in relapsed/refractory multiple myeloma), the dual-targeting P-CD19CD20-ALLO1 (B-cell malignancies and autoimmune indications including MS and SLE), and the solid-tumor program P-MUC1C-ALLO1, deepening Roche's bet that allogeneic CAR-Ts can broaden access relative to autologous cell therapies. Poseida was delisted from Nasdaq on close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Poseida Therapeutics (this deal) | 2024 | $1.5B | 60 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2024 deals · Roche Holding AG deals · Immunology deals